2025 Prescribing Trends for Tirzepatide: What's Changing?

The landscape of tirzepatide prescribing has transformed dramatically since its introduction. As we progress through 2025, prescribing patterns, provider specialties, access points, and clinical indications continue to evolve rapidly. This comprehensive analysis examines current trends, emerging shifts, and what they mean for patients seeking treatment. Drawing from prescription databases, insurance claims, provider surveys, and industry reports, we provide a data-driven perspective on the changing world of tirzepatide access.

Prescription Volume Trends

Overall Growth Trajectory

US prescription data (Jan 2024 - Jan 2025):

• Q1 2024: 1.2 million prescriptions
• Q2 2024: 1.6 million prescriptions (+33%)
• Q3 2024: 2.1 million prescriptions (+31%)
• Q4 2024: 2.4 million prescriptions (+14%)
• Q1 2025 projection: 2.8 million prescriptions (+17%)

Total annual prescriptions:

• 2023: 2.8 million
• 2024: 7.3 million
• 2025 projection: 11.2 million

Mounjaro vs Zepbound Split

Key trend: Weight loss indication (Zepbound) has overtaken diabetes indication (Mounjaro), reflecting growing recognition and acceptance of pharmacotherapy for obesity.

Provider Specialty Shifts

Prescriber Distribution (2025)

Primary Care Emergence

Factors driving primary care adoption:

1. Improved availability: Supply stabilization reduces referral need
2. Growing evidence base: Robust data increases provider confidence
3. Patient demand: Direct requests push primary care engagement
4. Simplified protocols: Standardized titration makes prescribing straightforward
5. CME expansion: Obesity medicine training in primary care
6. Reimbursement incentives: Better payment for obesity management

Specialist Perspectives

Endocrinologists:

• Focusing on complex cases (multiple comorbidities)
• Managing difficult-to-control diabetes
• Serving as referral centers for adverse events
• Relative share declining but absolute numbers increasing

Obesity Medicine Specialists:

• Comprehensive weight management programs
• Combination therapy approaches
• Post-bariatric weight regain management
• Growing but limited by specialist shortage

Telehealth Revolution

Telehealth Platform Growth

Prescription source evolution:

• Q1 2024: 22% of prescriptions from telehealth
• Q4 2024: 35% from telehealth
• Q1 2025: 41% from telehealth
• Projection Q4 2025: 48% from telehealth

Major Telehealth Providers

Market share (weight loss telehealth, 2025):

1. Hims & Hers: 28% market share
2. Ro (Ro Body): 24% market share
3. Noom Med: 15% market share
4. Henry Meds: 12% market share
5. Calibrate/Found/Others: 21% combined

Telehealth Advantages

• Convenience: No office visits required
• Lower barriers: Easier access for rural or time-constrained patients
• Competitive pricing: Often includes medication in subscription
• Rapid onboarding: Treatment initiation within days
• Regular check-ins: Built-in monitoring and support
• Compounded options: Many offer both branded and compounded

Telehealth Concerns

• Variable provider qualifications and oversight
• Limited physical examination and lab monitoring
• Potential for inappropriate prescribing
• Quality concerns with some compounded sources
• State licensing complexity

Regulatory Landscape

2025 policy environment:

• DEA rules allowing telehealth prescribing extended through 2025
• Some states implementing stricter telehealth prescribing requirements
• Increased scrutiny of compounding pharmacy partnerships
• Medical boards investigating inappropriate prescribing patterns

Insurance Coverage Evolution

Coverage Trends

Commercial insurance (2025):

• Mounjaro (diabetes): 82% of plans cover (up from 76% in 2024)
• Zepbound (weight loss): 34% of plans cover (up from 18% in 2024)
• Average copay with coverage: $25-150 for diabetes, $75-300 for weight loss

Medicare:

• Part D covers Mounjaro for diabetes: ~90% of plans
• Does NOT cover Zepbound for weight loss (federal restriction)
• Advocacy efforts ongoing to change coverage rules

Medicaid:

• State-by-state variation
• 15 states expanded coverage for weight loss GLP-1s in 2024
• Additional 8 states considering expansion in 2025

Prior Authorization Trends

Approval rates (2025):

• Initial diabetes approval: 76% (up from 68%)
• Initial weight loss approval: 42% (up from 28%)
• Appeal success rate: 58% (slightly improved)

Streamlining efforts:

• Some insurers implementing faster "auto-approval" pathways
• Standardized prior authorization forms reducing administrative burden
• Real-time benefit check tools improving efficiency

Employer Coverage

Self-insured employer plans:

• Offering weight loss GLP-1 coverage: 48% (up from 32% in 2024)
• Reasoning for expansion: ROI studies showing long-term healthcare cost savings
• Innovative approaches: Some employers covering as preventive care

Expanding Clinical Indications

Current FDA-Approved Uses

• Type 2 diabetes (Mounjaro): May 2022
• Chronic weight management (Zepbound): November 2023
• Sleep apnea (anticipated): Mid-2025

Off-Label Use Patterns

Common off-label indications (provider survey, n=1,200):

• Prediabetes with obesity: 68% of providers report prescribing
• PCOS with insulin resistance: 42% prescribe
• NAFLD/NASH: 38% prescribe
• Post-bariatric weight regain: 52% prescribe
• Cardiovascular risk reduction: 31% prescribe

Future Indication Pipeline

Trials underway or planned:

• Heart failure with preserved ejection fraction (HFpEF): Phase 3 ongoing
• Chronic kidney disease: Phase 3 planned
• NASH/MASH: Phase 2 completed, Phase 3 consideration
• Alzheimer's disease prevention: Exploratory studies

Impact of Sleep Apnea Approval

Expected changes (mid-2025 onwards):

• Prescription increase projected at 25-30%
• Improved insurance coverage for OSA patients
• New prescriber entry: sleep medicine specialists
• Potential Medicare coverage pathway (OSA is not explicitly obesity)
• Integration with sleep clinic workflows

Supply and Access Dynamics

Supply Evolution

Historical shortage timeline:

• Q2-Q4 2023: Severe shortages, intermittent availability
• Q1-Q2 2024: Moderate shortages, improving but inconsistent
• Q3-Q4 2024: Substantial improvement, most doses available
• Q1 2025: Near-normal supply for most strengths

Remaining challenges:

• Occasional shortages of starter doses (2.5mg, 5mg)
• Higher doses (12.5mg, 15mg) sometimes limited
• Geographic variation in pharmacy stock
• Demand growth still outpacing production increases

Compounded Tirzepatide Trends

Market evolution:

• Peak usage (Q2 2024): ~35% of tirzepatide users on compounded versions
• Current (Q1 2025): ~28% using compounded
• Trend direction: Decreasing as branded supply improves and FDA scrutiny increases

FDA actions affecting compounding:

• Updated shortage list removing tirzepatide intermittently
• Increased inspections of compounding pharmacies
• Warning letters to some compounders for quality issues
• Guidance on salt form distinctions (semaglutide sodium vs base)

Dosing and Titration Patterns

Dose Distribution

Current prescriptions by dose (Q1 2025):

• 2.5mg (starter): 18%
• 5mg: 22%
• 7.5mg: 15%
• 10mg: 19%
• 12.5mg: 14%
• 15mg (maximum): 12%

Titration Approach Changes

Standard protocol evolution:

• Original trials: Increase every 4 weeks
• 2024 practice: Many providers extending to 6-8 weeks per dose
• 2025 trend: Personalized titration based on tolerability and results

Emerging strategies:

• Slower escalation: 6-8 week intervals improving tolerability
• Maintenance at submaximal doses: 35% stay below 15mg if effective
• Dose reduction after goal: Some providers testing maintenance at lower doses
• Intermittent dosing: Experimental approaches every 10-14 days

Patient Demographics and Characteristics

Age Distribution

Trend: Slight shift toward younger patients as weight loss indication grows.

Socioeconomic Patterns

Income distribution:

• High income (>$100k): 42% of patients
• Middle income ($50-100k): 38% of patients
• Lower income (<$50k): 20% of patients

Access barriers: Cost remains prohibitive for lower-income patients without insurance coverage.

Geographic Distribution

Regional prescription rates (per 1000 adults with obesity):

• Northeast: 42 prescriptions per 1000
• West Coast: 38 per 1000
• South: 28 per 1000
• Midwest: 24 per 1000
• Rural areas: 18 per 1000

Disparity drivers:

• Provider availability and comfort
• Insurance coverage variations
• Telehealth adoption rates
• Socioeconomic factors

2025-2026 Outlook

Prescription Growth Projections

• 2025 total: 11.2 million prescriptions
• 2026 projection: 15.8 million prescriptions (+41%)
• 2027 projection: 20.5 million prescriptions (+30%)

Key Drivers of Continued Growth

1. Sleep apnea indication: Opens new patient population
2. Improved insurance coverage: Gradual expansion of weight loss coverage
3. Primary care adoption: Mainstream acceptance accelerating
4. Real-world evidence: Strong outcomes driving demand
5. Supply stabilization: Reliable availability enabling growth
6. Telehealth maturation: Easier access driving adoption

Potential Headwinds

• Cost sustainability: Payer pushback on budget impact
• Regulatory changes: Potential telehealth or compounding restrictions
• Competition: New GLP-1 and combination medications
• Long-term safety signals: Ongoing post-market surveillance
• Market saturation: Eventually reaching maximum addressable population

Innovation Horizon

Developments that could reshape prescribing:

• Oral tirzepatide: Phase 2 trials showing promise
• Once-monthly formulations: In development
• Triple agonists: Even more potent next-generation medications
• Biosimilars: Not expected until 2038-2040 due to patents
• Combination therapies: Tirzepatide + other agents

Key Takeaways

• Tirzepatide prescribing has grown to 11.2 million annual prescriptions, with Zepbound (weight loss) now comprising 62% of prescriptions
• Primary care physicians now account for 38% of prescriptions, surpassing endocrinologists as the largest prescriber group
• Telehealth platforms represent 41% of prescriptions and are projected to reach 48% by end of 2025
• Insurance coverage for weight loss indication has improved to 34% of commercial plans (up from 18% in 2024)
• Supply constraints have largely resolved, though occasional shortages of specific doses persist
• Anticipated FDA approval for sleep apnea indication expected to drive 25-30% prescription increase
• Compounded tirzepatide usage is declining (now 28%) as branded supply improves and FDA scrutiny increases
• Prescribing patterns show geographic and socioeconomic disparities, with access remaining limited for lower-income patients
• Innovation pipeline includes oral formulations, monthly dosing, and more potent next-generation medications
• Projected growth to 15.8 million prescriptions in 2026 driven by expanded indications and improved access

Frequently Asked Questions